MX377103B - Composicion farmaceutica solida que comprende amlodipino y losartan. - Google Patents

Composicion farmaceutica solida que comprende amlodipino y losartan.

Info

Publication number
MX377103B
MX377103B MX2017004032A MX2017004032A MX377103B MX 377103 B MX377103 B MX 377103B MX 2017004032 A MX2017004032 A MX 2017004032A MX 2017004032 A MX2017004032 A MX 2017004032A MX 377103 B MX377103 B MX 377103B
Authority
MX
Mexico
Prior art keywords
amlodipine
pharmaceutical composition
losartan
disintegrant
pharmaceutically acceptable
Prior art date
Application number
MX2017004032A
Other languages
English (en)
Other versions
MX2017004032A (es
Inventor
Ho Taek Im
Jae Hyun Park
Jong Soo Woo
Leedong Roh
Yong Il Kim
Young Su Yoon
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2017004032A publication Critical patent/MX2017004032A/es
Publication of MX377103B publication Critical patent/MX377103B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención proporciona una composición farmacéutica para la prevención o el tratamiento de trastornos cardiovasculares que contienen losartán o una sal farmacéuticamente aceptable del mismo; amlodipino o una sal farmacéuticamente aceptable del mismo; un desintegrante; y un agente de revestimiento. La composición de la presente invención, la cual tiene la mejor combinación y relación óptima de un desintegrante a un agente de revestimiento, muestra resistencia suficiente y altas tasas de disolución bajo varios ambientes de pH, y de esta manera, es útil para la preparación de una formulación sólida excelente que muestra eficiencia de suministro de fármaco y estabilidad de almacenamiento mejoradas.
MX2017004032A 2014-09-30 2015-09-01 Composicion farmaceutica solida que comprende amlodipino y losartan. MX377103B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140131834 2014-09-30
PCT/KR2015/009203 WO2016052866A1 (en) 2014-09-30 2015-09-01 Solid pharmaceutical composition comprising amlodipine and losartan

Publications (2)

Publication Number Publication Date
MX2017004032A MX2017004032A (es) 2017-07-07
MX377103B true MX377103B (es) 2025-03-07

Family

ID=55630854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004032A MX377103B (es) 2014-09-30 2015-09-01 Composicion farmaceutica solida que comprende amlodipino y losartan.

Country Status (20)

Country Link
US (1) US10034862B2 (es)
JP (1) JP2017530137A (es)
KR (1) KR102369607B1 (es)
CN (2) CN112716951A (es)
AR (1) AR101860A1 (es)
CO (1) CO2017003913A2 (es)
CR (1) CR20170125A (es)
DO (1) DOP2017000084A (es)
EC (1) ECSP17022124A (es)
JO (1) JO3435B1 (es)
MX (1) MX377103B (es)
MY (1) MY188302A (es)
PH (1) PH12017500536A1 (es)
RU (1) RU2698703C2 (es)
SG (1) SG11201702364VA (es)
SV (1) SV2017005417A (es)
TW (1) TWI681773B (es)
UY (1) UY36331A (es)
WO (1) WO2016052866A1 (es)
ZA (1) ZA201703015B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
MX2019005230A (es) * 2016-11-15 2019-08-14 Hanmi Pharm Ind Co Ltd Preparacion de complejo farmaceutica que comprende amlodipina, losartan y rosuvastatina.
CN115666564B (zh) * 2020-06-09 2024-07-16 韩美药品株式会社 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2179067A1 (en) 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
WO2010026470A1 (en) 2008-09-04 2010-03-11 Aurobindo Pharma Limited Stable dosage forms of antihypertensive agents
CN102292085B (zh) * 2009-01-23 2017-01-18 韩美科学株式会社 包含氨氯地平和氯沙坦的固体药物组合物及其制备方法
KR101888692B1 (ko) * 2011-03-25 2018-09-20 한미사이언스 주식회사 로자탄, 암로디핀 및 히드로클로로티아지드를 함유하는 고정 조합 투여 제형 조성물
KR101861307B1 (ko) 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물

Also Published As

Publication number Publication date
UY36331A (es) 2016-04-29
RU2017114993A3 (es) 2019-04-05
CO2017003913A2 (es) 2017-04-28
PH12017500536A1 (en) 2017-08-07
RU2017114993A (ru) 2018-11-05
ZA201703015B (en) 2019-07-31
CN107018650B (zh) 2021-02-02
CN107018650A (zh) 2017-08-04
CN112716951A (zh) 2021-04-30
WO2016052866A1 (en) 2016-04-07
TWI681773B (zh) 2020-01-11
DOP2017000084A (es) 2017-07-31
KR20160038734A (ko) 2016-04-07
US10034862B2 (en) 2018-07-31
KR102369607B1 (ko) 2022-03-03
JP2017530137A (ja) 2017-10-12
JO3435B1 (ar) 2019-10-20
RU2698703C2 (ru) 2019-08-29
MX2017004032A (es) 2017-07-07
AR101860A1 (es) 2017-01-18
ECSP17022124A (es) 2018-05-31
CR20170125A (es) 2017-07-06
SV2017005417A (es) 2017-10-13
US20170326110A1 (en) 2017-11-16
TW201617075A (zh) 2016-05-16
SG11201702364VA (en) 2017-05-30
MY188302A (en) 2021-11-26

Similar Documents

Publication Publication Date Title
EP4501932A3 (en) Kras g12c inhibitors
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2018003105A1 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos.
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EP4302830A3 (en) Quinazoline derivatives used to treat hiv
MX2018010983A (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
NZ721298A (en) Pharmaceutical compositions comprising azd9291
AR093705A1 (es) Depsipeptido y sus usos
MX2017014994A (es) Formulacion solida oral que contiene irinotecano y metodo de preparacion de la misma.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
PH12016502527B1 (en) Stabilized desmopressin
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
PH12018502490A1 (en) Oral tipepidine preparation

Legal Events

Date Code Title Description
FG Grant or registration